407 related articles for article (PubMed ID: 19142967)
1. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer.
Lanigan F; McKiernan E; Brennan DJ; Hegarty S; Millikan RC; McBryan J; Jirstrom K; Landberg G; Martin F; Duffy MJ; Gallagher WM
Int J Cancer; 2009 May; 124(9):2088-97. PubMed ID: 19142967
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
3. CTEN (C-terminal tensin-like), a novel oncogene overexpressed in invasive breast carcinoma of poor prognosis.
Albasri A; Aleskandarany M; Benhasouna A; Powe DG; Ellis IO; Ilyas M; Green AR
Breast Cancer Res Treat; 2011 Feb; 126(1):47-54. PubMed ID: 20390342
[TBL] [Abstract][Full Text] [Related]
4. Expression of ghrelin is correlated to a favorable outcome in invasive breast cancer.
Grönberg M; Fjällskog ML; Jirström K; Janson ET
Acta Oncol; 2012 Mar; 51(3):386-93. PubMed ID: 22067021
[TBL] [Abstract][Full Text] [Related]
5. Novel prognostic markers for patients with triple-negative breast cancer.
Zhou L; Li K; Luo Y; Tian L; Wang M; Li C; Huang Q
Hum Pathol; 2013 Oct; 44(10):2180-7. PubMed ID: 23845466
[TBL] [Abstract][Full Text] [Related]
6. JAM-A expression positively correlates with poor prognosis in breast cancer patients.
McSherry EA; McGee SF; Jirstrom K; Doyle EM; Brennan DJ; Landberg G; Dervan PA; Hopkins AM; Gallagher WM
Int J Cancer; 2009 Sep; 125(6):1343-51. PubMed ID: 19533747
[TBL] [Abstract][Full Text] [Related]
7. The mRNA expression of inhibitors of DNA binding-1 and -2 is associated with advanced tumour stage and adverse clinical outcome in human breast cancer.
Wazir U; Jiang WG; Sharma AK; Newbold RF; Mokbel K
Anticancer Res; 2013 May; 33(5):2179-83. PubMed ID: 23645773
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer.
Esslimani-Sahla M; Simony-Lafontaine J; Kramar A; Lavaill R; Mollevi C; Warner M; Gustafsson JA; Rochefort H
Clin Cancer Res; 2004 Sep; 10(17):5769-76. PubMed ID: 15355905
[TBL] [Abstract][Full Text] [Related]
9. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
Arihiro K; Oda M; Ogawa K; Tominaga K; Kaneko Y; Shimizu T; Matsumoto S; Oda M; Kurita Y; Taira Y
Jpn J Clin Oncol; 2013 Jan; 43(1):55-62. PubMed ID: 23225912
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression.
Demir H; Turna H; Can G; Ilvan S
J BUON; 2010; 15(4):774-82. PubMed ID: 21229645
[TBL] [Abstract][Full Text] [Related]
11. Elevated Interleukin-13 Receptor Alpha 1 Expression in Tumor Cells Is Associated with Poor Prognosis in Patients with Invasive Breast Cancer.
Park MH; Kwon HJ; Kim JR; Lee B; Lee SJ; Bae YK
Ann Surg Oncol; 2017 Nov; 24(12):3780-3787. PubMed ID: 28634667
[TBL] [Abstract][Full Text] [Related]
12. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
13. Differential TAG-72 epitope expression in breast cancer and lymph node metastases: a marker of a more aggressive phenotype.
Galietta A; Pizzi C; Pettinato G; Limite G; Sgambato A; Lamberti M; Muraro R; Formisano C; Pensabene M; Bianco AR; Mariani-Costantini R; Contegiacomo A
Oncol Rep; 2002; 9(1):135-40. PubMed ID: 11748471
[TBL] [Abstract][Full Text] [Related]
14. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.
Trastour C; Benizri E; Ettore F; Ramaioli A; Chamorey E; Pouysségur J; Berra E
Int J Cancer; 2007 Apr; 120(7):1451-8. PubMed ID: 17245699
[TBL] [Abstract][Full Text] [Related]
15. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
16. Molecular markers of therapeutic resistance in breast cancer.
Zhou L; Luo Y; Li K; Tian L; Wang M; Li C; Huang Q
Hum Pathol; 2013 Jul; 44(7):1421-8. PubMed ID: 23434145
[TBL] [Abstract][Full Text] [Related]
17. Relationship between IL-10 expression and prognosis in patients with primary breast cancer.
Li Y; Gao P; Yang J; Yu H; Zhu Y; Si W
Tumour Biol; 2014 Nov; 35(11):11533-40. PubMed ID: 25129439
[TBL] [Abstract][Full Text] [Related]
18. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
Ulas A; Kos T; Avci N; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
Asian Pac J Cancer Prev; 2015; 16(4):1643-9. PubMed ID: 25743846
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of histopathologic changes and expression of biomarkers in breast carcinoma before and after neoadjuvant chemotherapy].
Zheng S; Zhang BL; Xiao T; Zou SM; Xue LY; Luo W; Guo L; Liu XY; Lü N
Zhonghua Bing Li Xue Za Zhi; 2011 Jul; 40(7):465-70. PubMed ID: 22088373
[TBL] [Abstract][Full Text] [Related]
20. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
